Pharmacology

Drug Development Drug Mechanisms Psychedelics Psychoactive Substances Cannabinoids Drug Safety Opioids Hormones Synthetic Drugs Psychedelic Substances

FDA Clears First U.S. Human Trial of Ibogaine Derivative for Alcohol Use Disorder

The FDA move signals a federal shift to speed psychedelic studies under new White House directives.

Definium Therapeutics Jumps to 52-Week High After Trump Order on Psychedelic Treatments

Trump Signs Order to Fast-Track Psychedelic Treatments

Experimental Drug Elraglusib Extends Survival in Phase 2 Pancreatic Cancer Trial

EPO Signals Patent Grant for Silo Pharma’s PTSD Prevention Approach

CDC Issues National Alert on Veterinary Sedative Medetomidine in Fentanyl Supply

NIH Identifies DFNZ, a Nitazene Opioid That Eased Pain in Rats Without Breathing Risks

U.S. Kratom Poisoning Reports Hit Record in 2025, CDC Study Finds

CDC Report Finds Record U.S. Kratom Poison Calls in 2025

Artelo Secures Fully Funded Investigator-Led Glaucoma Trial With Belfast Health Trust

GLP‑1 Use Under Scrutiny After Study on Tolerability and Delhi OTC Sales

NCI Pursues Preclinical Test of Ivermectin’s Anti-Cancer Activity

New Study Finds UK Nitazene Deaths Likely Undercounted by Up to a Third

GLP-1 Weight-Loss Boom Triggers Safety Warnings and New Oversight

Randomized Trial Finds Solriamfetol Improves Alertness in Early-Morning Shift Workers

Utah Panel Advances Kratom Ban as Lawmakers Split on Regulation

Liraglutide Patent Expiry Triggers Cheaper Weight‑Loss Generics in Germany

FDA Approves First Oral Wegovy Weight-Loss Pill as U.S. Availability Begins

Major JAMA Review Finds Weak Evidence for Most Medical Cannabis Uses

First GLP‑1 Implant Trial for Obese Cats Begins With First Patient Dosed